Is gabapentin a sedative? Understanding its sedating effects

Gabapentin is classified as an anti-epileptic (antiseizure) medicine in the BNF and is also widely prescribed for neuropathic pain. It is not classified as a sedative or hypnotic.

However, the distinction matters less in practice than in pharmacology textbooks.

Gabapentin causes significant sedation in many patients, and this is one of its most frequently reported side effects.

What gabapentin is licensed for in the UK:

• Epilepsy: as adjunctive therapy for focal seizures with or without secondary generalisation
• Neuropathic pain: peripheral neuropathic pain in adults

Off-label uses (not formally licensed but commonly prescribed):

• Generalised anxiety disorder
• Migraine prophylaxis
• Restless legs syndrome
• Insomnia, particularly when associated with pain
• Alcohol withdrawal support

Since April 2019, gabapentin has been a Schedule 3 controlled substance in the UK under the Misuse of Drugs Regulations, reflecting concerns about misuse and dependence potential.

Despite its name suggesting an interaction with GABA (gamma-aminobutyric acid), gabapentin does not bind directly to GABA receptors. Its sedating effects arise from a different mechanism.

Primary mechanism:

Gabapentin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system.

This reduces the influx of calcium into nerve terminals, which in turn decreases the release of excitatory neurotransmitters such as glutamate, noradrenaline and substance P.

How this causes sedation:

• Reduced excitatory neurotransmission leads to an overall calming effect on the nervous system
• Decreased noradrenaline release contributes to relaxation and drowsiness
• The effect on thalamocortical circuits may promote sleep

Comparison with true sedatives:

• Benzodiazepines (e.g. diazepam) directly enhance GABA-A receptor activity, producing rapid and pronounced sedation
• Z-drugs (e.g. zopiclone) also act on GABA-A receptors at the benzodiazepine binding site
• Gabapentin works indirectly, producing a gentler sedation that many patients describe as a "calming" rather than a "knockout" effect

This difference in mechanism is clinically relevant.

Gabapentin's sedation is generally less intense than that of benzodiazepines, and the risk of respiratory depression as a single agent is lower (though not absent).

While sedation is often listed as an unwanted side effect, gabapentin's calming properties can sometimes be therapeutically useful.

Sleep disturbance in chronic pain:

Patients with neuropathic pain frequently suffer from poor sleep. Gabapentin can address both the pain and the insomnia simultaneously.

Taking the larger portion of the daily dose at bedtime can improve sleep quality without necessarily needing a separate sleeping tablet.

Anxiety-related insomnia:

Gabapentin is sometimes used off-label for generalised anxiety, and its sedating properties can help patients who struggle with anxiety-driven sleeplessness.

Pre-operative anxiety:

Some anaesthetists prescribe gabapentin as a pre-medication before surgery to reduce anxiety and improve post-operative pain control. Its sedating effect is part of its usefulness in this context.

Alcohol withdrawal:

During alcohol withdrawal, patients often experience insomnia, anxiety and agitation. Gabapentin's sedating and anxiolytic properties can be helpful as part of a detoxification regimen.

Important considerations:

• Sedation should be a welcome effect, not just a tolerated one. If drowsiness interferes with your daily life, speak to your prescriber
• The sedating effect tends to reduce with continued use (tolerance develops)
• NICE does not recommend gabapentin as a first-line treatment for insomnia alone

If gabapentin's sedating effects are troublesome rather than helpful, there are several strategies to consider.

Dose and timing adjustments:

• Shift more of the dose to bedtime: if you take gabapentin three times daily, ask your prescriber about taking a smaller morning dose and a larger evening dose
• Slow titration: increasing the dose more gradually can help the body adjust. The BNF recommends gradual dose escalation
• Dose reduction: if sedation is severe, a lower total daily dose may still provide adequate pain relief or seizure control with less drowsiness

Lifestyle measures:

• Avoid other sedating substances, including alcohol, antihistamines and over-the-counter sleep aids
• Maintain a regular sleep-wake cycle to reduce daytime drowsiness
• Stay physically active during the day, as exercise can counteract fatigue
• Limit caffeine to the morning hours

When to review treatment:

• If sedation persists beyond the first 2 to 4 weeks at a stable dose
• If drowsiness is affecting your work, driving or quality of life
• If you are also taking opioids or benzodiazepines (discuss the combination urgently with your prescriber)

Alternative medicines for neuropathic pain, such as amitriptyline or duloxetine, have different side effect profiles and may be better tolerated in some patients.

NICE guidance on neuropathic pain recommends trying alternatives if the first-choice treatment is not suitable.

Pregabalin (Lyrica) is pharmacologically similar to gabapentin and also causes sedation. Many patients and prescribers wonder how the two compare.

Key differences:

• Pregabalin has a higher oral bioavailability (approximately 90% compared to gabapentin's variable 30-60%) and a more predictable dose-response relationship
• Pregabalin tends to produce more consistent sedation at therapeutic doses
• Gabapentin's absorption is saturable, meaning that higher doses do not necessarily produce proportionally greater effects, including sedation
• Both are Schedule 3 controlled substances in the UK

Clinical implications:

• Patients who find gabapentin too sedating may not necessarily tolerate pregabalin better, as the mechanism is the same
• Conversely, patients who tolerate gabapentin well may find pregabalin more sedating
• Switching between the two should be done under medical supervision with gradual cross-titration

What the evidence says:

NICE does not express a preference between gabapentin and pregabalin for neuropathic pain, noting that the choice should be individualised based on response and tolerability.

Both carry similar warnings regarding sedation, misuse potential and the need for gradual dose changes.